T 1655/21 of 21.06.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T165521.20240621
- Date of decision
- 21 June 2024
- Case number
- T 1655/21
- Petition for review of
- -
- Application number
- 14742322.2
- IPC class
- A61K 47/40C08B 37/16
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- CYCLODEXTRIN
- Applicant name
- Curadev Pharma Pvt. Ltd.
- Opponent name
- Ligand Pharmaceuticals Incorporated
- Board
- 3.3.03
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1)European Patent Convention R 103(1)(a)European Patent Convention R 103(3)(a)European Patent Convention R 111(2)European Patent Convention R 116Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 012(8)
- Keywords
- Decision in written proceedings
Submissions central to the appellant's case dealt with (no)
Appeal decision reasoned (no)
Reimbursement of appeal fee - (yes)
Remittal - fundamental deficiency in first-instance proceedings (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.
3. The appeal fee of the appellant is to be reimbursed. The appeal fee of the respondent is to be reimbursed at 50% in accordance with Rule 103(3)(a) EPC.